Novo Nordisk A/S (NYSE:NVO) Price Target Cut to $105.00 by Analysts at BMO Capital Markets

Novo Nordisk A/S (NYSE:NVO) had its target price lowered by BMO Capital Markets from $156.00 to $105.00 in a research note published on Monday,Benzinga reports. BMO Capital Markets currently has an outperform rating on the stock.

Several other equities analysts also recently issued reports on the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Trading Up 4.4 %

Shares of Novo Nordisk A/S stock opened at $88.71 on Monday. The firm’s 50 day simple moving average is $109.01 and its two-hundred day simple moving average is $124.95. The firm has a market capitalization of $398.09 billion, a price-to-earnings ratio of 28.71, a PEG ratio of 1.37 and a beta of 0.40. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S during the third quarter valued at $28,000. Abound Wealth Management increased its holdings in Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after buying an additional 157 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the third quarter worth about $42,000. Finally, Carolina Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $48,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.